Getting Started10 min readSeptember 11, 2025

    Buy Semaglutide in St. Petersburg — $99/Month | Trimi Health

    GLP-1 weight loss treatment in St. Petersburg — shipped directly to your St. Petersburg address in 3–5 business days. No clinic visits, no insurance required, just $99/month for compounded semaglutide.

    Why St. Petersburg Residents Choose Telehealth for Semaglutide

    St. Petersburg is one of the most vibrant cities in Florida, with a population of ~258,000 in the city proper and ~3.2 million Tampa Bay in the greater metro area. Despite access to quality healthcare facilities, affordable GLP-1 weight loss medications remain a challenge for many St. Petersburg residents. In-person weight loss clinics in Downtown St. Pete and St. Pete Beach often charge $280–$520 per month, putting treatment out of reach for a significant portion of the population.

    St. Petersburg's adult obesity rate of approximately ~30% underscores the need for accessible weight management solutions. Many neighborhoods across St. Petersburg face disproportionately high rates of obesity and related conditions like type 2 diabetes, making affordable GLP-1 access especially important for the community's overall health.

    St. Petersburg GLP-1 Snapshot

    Population: ~258,000 city / ~3.2 million Tampa Bay metro. Adult obesity rate: ~30%. Typical clinic cost: $280–$520/mo. Brand Wegovy: $1,000–$1,400/mo. Trimi telehealth: $99/mo semaglutide, $125/mo tirzepatide.

    Telehealth eliminates the barriers of travel time, parking, and clinic overhead that St. Petersburg residents face. Whether you live in Gulfport, Pinellas Park, or Clearwater, Trimi delivers compounded semaglutide directly to your door for a flat $99/month. Learn more about how telehealth prescribing works. You can also read about Ozempic vs. Wegovy or explore our GLP-1 beginner guide.

    St. Petersburg Pricing: Trimi vs Local Providers & Pharmacies

    St. Petersburg's weight loss market includes med-spas, functional medicine practices, and traditional clinics. Here is how Trimi compares to local options in the St. Petersburg area.

    OptionMonthly CostIn-Person VisitInsurance Required
    St. Petersburg Weight Loss Clinic (avg)$280–$520YesSometimes
    St. Petersburg Pharmacy (brand Wegovy)$1,000–$1,400YesRecommended
    Trimi Telehealth (compounded)$99/mo (sema) / $125/mo (tirz)NoNo

    Interested in understanding the difference between medications? Read our semaglutide vs. tirzepatide comparison.

    How It Works: 3 Steps to Get Semaglutide in St. Petersburg

    Step 1: Online Health Intake

    Complete a comprehensive health questionnaire covering your medical history, current medications, BMI, and weight loss goals — from anywhere in St. Petersburg.

    Step 2: Provider Review & Prescription

    A licensed provider evaluates your submission, confirms GLP-1 candidacy, and creates a dosing protocol. Your prescription is sent to a licensed compounding pharmacy.

    Step 3: Delivered to Your St. Petersburg Door

    Temperature-controlled packaging arrives at your St. Petersburg address within 3–5 business days. Monthly refills ship automatically.

    New to GLP-1 medications? Check out our guide on whether you qualify for GLP-1 treatment.

    Available Medications for St. Petersburg Residents

    Compounded Semaglutide

    $99/month

    • Same active ingredient as Wegovy
    • Weekly self-injection
    • ~15% average weight loss at 68 weeks
    • No insurance required

    Compounded Tirzepatide

    $125/month

    • Dual GLP-1/GIP receptor agonist
    • Weekly self-injection
    • ~22% average weight loss at 72 weeks
    • No insurance required

    Unsure which medication fits your needs? Read our semaglutide vs. tirzepatide comparison for a detailed breakdown. You can also learn about compounded medication safety standards.

    Semaglutide and Weight Management in St. Petersburg

    For St. Petersburg residents considering semaglutide, combining medication with healthy lifestyle changes produces the best outcomes. St. Petersburg offers plenty of opportunities for physical activity, from local parks and trails to community fitness centers throughout the metro area. Pairing your semaglutide treatment with regular activity can enhance weight loss results significantly.

    Semaglutide works by mimicking the GLP-1 hormone to reduce appetite and slow gastric emptying. Clinical trials showed participants achieved ~15% average weight loss at 68 weeks. For St. Petersburg residents, Trimi makes this treatment accessible at $99/month with no insurance requirements and no clinic visits.

    Learn more about combining GLP-1 medication with diet and exercise to maximize your results. You might also find our guide on what to expect your first month on semaglutide helpful as you begin your journey.

    Getting Started with Trimi in St. Petersburg

    St. Petersburg residents with a BMI of 27 or higher (with at least one weight-related health condition) or a BMI of 30 or higher may be candidates for GLP-1 treatment through Trimi. The entire process — from online intake to first delivery — takes approximately 3–5 business days.

    Whether you're in Downtown St. Pete, St. Pete Beach, Clearwater, or anywhere in the greater St. Petersburg area, Trimi ships medication directly to your door. Explore our what to expect your first month on semaglutide or learn about managing GLP-1 side effects.

    Ready to Start in St. Petersburg?

    Get compounded semaglutide delivered to any St. Petersburg address for $99/month. No office visit, no insurance, no waiting room.

    Get Started for $99/Month

    Frequently Asked Questions: Semaglutide in St. Petersburg

    Can I get semaglutide in St. Petersburg without visiting a clinic?

    Yes. Trimi offers compounded semaglutide entirely through telehealth. St. Petersburg residents complete an online health intake, receive a provider evaluation, and get medication shipped directly to their St. Petersburg address — no in-person visit required.

    How much does semaglutide cost at St. Petersburg weight loss clinics?

    St. Petersburg-area weight loss clinics in neighborhoods like Downtown St. Pete, St. Pete Beach, and Gulfport typically charge $280–$520 per month for compounded semaglutide programs. Trimi delivers the same compounded semaglutide for $99/month — no clinic overhead, no office visit.

    How fast is shipping to St. Petersburg?

    Most St. Petersburg residents receive their compounded semaglutide within 3–5 business days after prescription approval. Medication ships directly to your St. Petersburg address — whether you're in Downtown St. Pete, Pinellas Park, or the surrounding St. Petersburg metro area.

    Is telehealth prescribing legal in Florida?

    Yes. Florida law permits licensed providers to conduct telehealth evaluations and prescribe medications including GLP-1 agonists. Trimi connects St. Petersburg residents with licensed providers who manage evaluation, prescribing, and ongoing care entirely online.

    Does Trimi offer tirzepatide as well as semaglutide in St. Petersburg?

    Yes. Trimi offers both compounded semaglutide at $99/month and compounded tirzepatide at $125/month for St. Petersburg residents. During your online consultation, a licensed provider will help determine which medication best fits your health goals.

    What makes St. Petersburg a high-need market for GLP-1 medications?

    St. Petersburg has an adult obesity rate of approximately ~30%. Many St. Petersburg residents lack access to affordable weight management options, making telehealth GLP-1 programs like Trimi a critical resource for accessible, physician-supervised treatment.

    Can I continue my Trimi treatment if I move within the St. Petersburg area?

    Yes. Because Trimi is a telehealth program, your care is tied to your account — not a specific clinic. Whether you move from Downtown St. Pete to Clearwater or anywhere else in the St. Petersburg metro, your treatment continues without interruption.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications requiring evaluation by a licensed healthcare provider. Individual results vary. Common side effects include nausea, vomiting, diarrhea, and constipation. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. Pinellas County Health Department Community Assessment 2023
    5. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Start your GLP-1 journey — from $99/mo

    Get Started